The argument for AI in clinical trials is often made in the abstract: faster, cheaper, smarter. That framing is easy to dismiss. The concrete case is harder to ignore, and it is clearest in the least glamorous corner of the trial: the Trial Master File.

This post makes that concrete case. It looks at what regulators actually find wrong, where the manual workload genuinely sits, and how the new direction from the FDA and EMA frames AI as something to govern rather than fear. The throughline is simple. AI is most useful in clinical trials where the work is high-volume, rule-bound, and inspection-critical, and almost nowhere is that more true than in keeping the TMF complete and ready.

The TMF is where the hours quietly disappear

A Trial Master File is the complete record that a trial was conducted properly. It must be contemporaneous, complete, and inspection-ready at any moment, not reconstructed in a panic before an audit. For a lean CRO or a small sponsor running several studies at once, maintaining that file is a permanent, capacity-eating task.

The scale of the manual effort is striking. Industry reporting suggests that, even in 2025, the large majority of TMF documents are still processed by hand, with at least 95% handled manually according to internal data cited by TMF software vendor Medable (Medable). Every one of those documents is read, classified into the correct zone, given metadata, checked for quality, and filed. Multiply that by hundreds or thousands of documents per study, across multiple concurrent trials, and the bottleneck is obvious.

What inspectors actually find

This manual burden shows up directly in inspection outcomes. In UK MHRA Good Clinical Practice inspections, record keeping and essential documents are consistently among the most common areas of findings. Recurring themes include:

  • TMFs that are incomplete because the defined scope missed essential documents, or required documents were simply never filed.
  • Weak version control and document management, leading to missing version histories and inconsistencies between protocols and supporting documents.
  • Undefined TMF scope, where no clear process exists for capturing all components, including those held by third parties, producing “TMF data sprawl” across systems and providers (Ennov on MHRA TMF findings).

The EMA’s GCP findings tell a similar story, with completeness and oversight of the file repeatedly flagged (Arkivum on EMA 2024 GCP findings). These are not exotic failures. They are the predictable result of asking a small team to hand-maintain a large, fast-moving file with perfect consistency. That is exactly the kind of work machines do well and people find draining.

The regulators are not saying “no” to AI. They are saying “govern it”

A common reason teams hesitate is the fear that regulators will penalise AI use. The recent direction of travel says otherwise: the message is that AI is acceptable, even expected, provided it is used responsibly with human oversight.

The clearest signal came in January 2026, when the FDA and EMA jointly proposed ten principles for good AI practice in medicine development. The principles give broad guidance on AI use across the product lifecycle, from early research and clinical trials through to manufacturing and safety monitoring, and were described as “a first step of a renewed EU-US cooperation in the field of novel medical technologies” (European Pharmaceutical Review; EMA).

This builds on a deliberate, multi-year regulatory effort rather than a sudden reaction:

  • The FDA published draft guidance in 2025, “Considerations for the Use of Artificial Intelligence to Support Regulatory Decision Making for Drug and Biological Products,” setting out a risk-based credibility framework, and maintains a dedicated AI in drug development programme (FDA: Artificial Intelligence for Drug Development).
  • The EMA published its AI reflection paper in 2024, runs a coordinated AI Work Plan with the Heads of Medicines Agencies extending to 2028, and in March 2025 issued its first qualification opinion on an AI methodology for a clinical trial, a concrete sign that AI methods can earn regulatory acceptance when properly validated.

The consistent theme across all of this is human oversight, risk proportionality, transparency, and data quality. None of it endorses fully automated decisions. As of 2025, no regulator has issued guidance endorsing fully automated AI classification of TMF documents, which is exactly why responsible products keep a human in the loop.

What “AI done responsibly” looks like for the TMF

At PharmaTrialsCortex we follow one rule across every AI capability: AI is advisory, humans decide. Applied to the Trial Master File, that means SmartTMF classifies, files and scores readiness automatically while people stay in control of every consequential step.

In practice:

  • Classification and filing. AI reads each document, proposes the correct TMF category and zone, and extracts the metadata, then a person confirms. A three-person team files with the consistency of a much larger one.
  • Missing-document detection. The system compares what has been filed against the expected documents for each study, country, and site, and flags gaps against trial milestones, the precise completeness problem inspectors cite most.
  • Inspection-readiness scoring. A live readiness score across every study replaces the pre-inspection scramble with a number you can check at any time.
  • Confidence and audit. Low-certainty AI suggestions are surfaced for closer review, and every action, AI-proposed or human-made, is recorded in an immutable audit trail.

This is what keeps the approach defensible. The advisory-with-oversight design lines up with GDPR Article 22, which restricts solely automated decisions with significant effects, and with the human-oversight emphasis running through the FDA and EMA principles. The same discipline underpins the regulatory controls behind our AI, which are designed and aligned to 21 CFR Part 11, EU Annex 11, ICH-GCP E6(R3), and ALCOA++ data integrity.

The honest version of the pitch

AI will not run your trial for you, and you should be wary of anyone who says it will. What it will do is take the high-volume, repetitive, error-prone filing and quality work that currently consumes your team and inflates your inspection risk, and turn it into reviewed, audited, consistent output. The regulatory ground has shifted from “should we allow this” to “how do we govern it well,” and the document-heavy TMF is the most obvious place to start.

If your team is feeling the TMF squeeze across multiple studies, book a discovery call and see SmartTMF on one of your live studies. For the standards context driving more of this work, read our piece on the CDISC TMF Standard in 2026, and for the EDC and data-management side of AI in trials, see how AI is transforming clinical data management.

Sources: FDA Artificial Intelligence for Drug Development; EMA and FDA common principles for AI in medicine development; European Pharmaceutical Review on the joint AI guidance; MHRA TMF inspection findings (Ennov); Medable on manual TMF processing. This article is general information, not regulatory advice. Verify current guidance against primary FDA, EMA and MHRA sources before acting.